Biotechnology
Latest news, analysis, and insights from ASX biotechnology companies
EBR Systems Resets US Sales Strategy after WiSE Implant Slowdown
EBR Systems resets its US sales strategy after WiSE implants fell to 40 in the September quarter, as Medicare reimbursement rates rise by up to 93%.
Latest Stories — SECTOR DESK
Racura Oncology Advances to New RC220 Dose Level in Harness-1 Lung Cancer Trial
Racura Oncology can escalate RC220 to 100mg/sqm in its lung cancer trial after no safety concerns emerged at the initial dose.
Clarity Pharmaceuticals Hits SECuRE Cohort Expansion Main Group Recruitment Target
Clarity Pharmaceuticals hits SECuRE main-group recruitment target, advancing its prostate cancer therapy trial as Phase III planning gets underway.
Cyclopharm’s Technegas Named as Preferred Ventilation Agent for Lung Imaging in China
Cyclopharm’s Technegas unanimously recommended as China’s preferred ventilation agent for lung imaging by seven leading medical bodies.
Optiscan Imaging Moves Closer to Regulatory Clearance of Real-Time Surgical Imaging Platform
Optiscan Imaging submits InVue for FDA 510(k) review, moving its real-time surgical imaging platform closer to US clearance and commercialisation.
Dimerix Achieves First Patient Completion Milestone for DMX-200 Clinical Program
Dimerix’s DMX-200 program reaches a milestone as its first patient completes two years in the extension study, with 93% of eligible patients continuing.
Artrya Wins Five-Year US Commercial Deal with Huntsville Hospital Health System
Artrya lands five-year US deal with Huntsville Hospital Health System; minimum US$0.5m for Salix Coronary Anatomy SaaS, expanding its US footprint.
Syntara Expands Safety and Tolerability Study of SNT-9465 Topical Scar Treatment
Syntara expands Phase 1b trial for SNT-9465, adding 10 participants, new blinded design and Sydney site; top-line data due Q1 2027 to back an IND.
LTR Pharma Final Phase II Report Confirms Fast Absorption for Spontan Intranasal Spray in Treating ED
LTR Pharma's Spontan intranasal ED spray peaks in 10 minutes, six-fold faster than oral vardenafil; Phase II data complete, paving US licensing talks.
Vitrafy Life Sciences Expands Platelet Cryopreservation Program With Versiti Blood Health
Vitrafy Life Sciences expands platelet cryopreservation with Versiti; 94.4% post-thaw recovery from USAISR, two free units, US device listing aimed FY2027.
INOVIQ Defines EXO-OC Commercialisation Path after Independent Review
INOVIQ maps a 12–18 month path to US LDT for EXO-OC after independent review; aims for H1 2028 lab validation amid sample-handling variability.
Singular Health Group Signs Deal for Florida’s First State-Funded Medical Imaging Repository
Singular Health inks Florida deal for state-funded 3DICOM imaging repository with FIU, signalling first infrastructure revenue and potential Medicaid blueprint.